In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J’s Zytiga –The Anatomy Of A Cancer Launch

Executive Summary

Johnson & Johnson’s prostate cancer drug Zytiga is off to a brilliant launch. Payors are covering it with relatively few restrictions, medical oncologists are using it in advanced patients, and it has streaked ahead of its direct competitor Jevtana, a second-generation taxane, in part by grabbing new patient share from the same post-docetaxel population.


Related Content

J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
J&J Touts New Product Strength In 2012 Year-End Call
Can Zytiga Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?
FDA Approves Zytiga In Earlier Prostate Cancer Setting
Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?
With New Data For A Drug In Dispute, Aragon Raises $50 Million
Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch
The Future Of Oncology At J&J: An Interview With William Hait
With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts